A method for stratifying a subject on the basis of having experienced a prior event of the vasculature (acute) or having not experienced a prior event of the vasculature is described. The method comprises contacting a sample from the subject which comprises members associated with an event of the systemic vasculature with one or more binding partners of the members. The binding partners are immobilized to a solid support and the pattern of interaction between the members and the binding partners provides an assessment of the presence or absence or actual level or change in level of the event of the systemic vasculature such that an elevated level of at least seven members is indicative of an acute condition wherein no change in levels of the members is indicative of a subject not having experienced a prior event of the vasculature. The members are selected from .myoglobin, myosin light chain, myosin heavy chain, total creatine kinase, creatine kinase-MB, lactate dehydrogenase, aspartate aminotransferase, cardiac troponin I and T, fatty acid binding protein (FAB protein), glycogen phosphorylase-BB isoenzyme, alpha-atria natriuretic peptide, brain natriuretic peptide, adrenomedullin, low density lipoprotein, very low density lipoprotein, high density lipoprotein and intermediate density lipoprotein, C reactive protein, serum amyloid A, P-selectin, prostaglandins, platelet-activating factor, histamine, tumor necrosis factor alpha, soluble TNF receptor 2, fibrin, fibrinogen, fibronolytic peptides, modified haemoglobin, ferritin, soluble intercellular adhesion molecule (ICAM) including soluble intercellular adhesion molecule-1(ICAM1), heat shock proteins, apoB, apoA, apoE, homocysteine or parts thereof, Streptococcus sp., Porphyromonas gingivalis, Helicobacter pylori and Chlamydiapneumoniae or immunological relatives thereof, necrosis and platelet markers, leptin, vasopeptidase inhibitor of cardiac endogenous kinins, heparin, metalloproteinase-9, metalloproteinase-1 including its tissue inhibitor, angiotensin-converting enzyme, CD95/Apo1/Fas, hepatocyte growth factor, soluble vascular cell adhesion molecule-1, plasma brain natriuretic peptide, angiotensin II type receptor, endothelial constitutive nitric oxide synthase, glycoprotein IIIa genetic polymorphisms, factor VIIa, thrombin, endothelin-1, cardiac myofibrillar proteins, Fas and Fas ligand, ligands thereof or binding partners thereof or nucleic acid molecules encoding same or their fragments or ligands or binding partners. Also described is an array of binding partners and a method for determining the presence or absence of a condition or event of the systemic vasculature.
Diagnostic assay for vasculature by measuring multiple biological markers